E. Frei

发表

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Richard L Schilsky, Larry Norton, James N Ingle, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Weekly high-dose methotrexate and doxorubicin for osteosarcoma: the Dana-Farber Cancer Institute/the Children's Hospital--study III.

N. Jaffe, M. Link, M. Gebhardt, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preclinical studies and clinical correlation of the effect of alkylating dose.

B. Teicher, Y. Y. Wang, S. Holden, 1988, Cancer research.

Bone marrow autotransplantation for solid tumors--prospects.

B. Teicher, L. Schnipper, K. Antman, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.

C. Shapiro, R. Gelman, D. Hayes, 1993, Journal of the National Cancer Institute.

Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Etoposide (CHOPE) for Advanced-Stage Hodgkin's Disease: CALGB 8856

G. Petroni, F. Millard, B. Peterson, 2001, Cancer investigation.

Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC).

D. Sugarbaker, T. Lynch, G. Strauss, 1997, Lung cancer.

Continuous‐infusion cisplatin, 5‐fluorouracil, and leucovorin for advanced non‐small cell lung cancer

L. Kalish, D. Sugarbaker, T. Lynch, 1994, Cancer.

Selection bias in clinical trials.

W Wood, W. Wood, J. Greenberger, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor oxygenation and radiosensitization by pentoxifylline and a perflubron emulsion carbogen breathing.

B. Teicher, G. Schwartz, M. Robinson, 1993, International journal of oncology.

Decreased tumor oxygenation after cyclophosphamide, reoxygenation and therapeutic enhancement with a perflubron emulsion carbogen breathing.

B. Teicher, T. Kusumoto, G. Schwartz, 1993, International journal of oncology.

Chemotherapeutic strategies in the multidisciplinary treatment of head and neck cancer.

J. Anderson, J. Clark, C. Norris, 1988, Seminars in oncology.

Combination chemotherapy of advanced non-Hodgkin lymphoma with bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP).

D. Rosenthal, A. Skarin, E. Frei, 1977, Blood.

Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support.

B. Teicher, A. Elias, L. Schnipper, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.

Shaun Parsons, E. Guinan, P. Mauch, 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Continuous‐infusion cisplatin, 5‐fluorouracil, and bolus methotrexate in the treatment of advanced non‐small cell lung cancer

L. Kalish, T. Lynch, A. Elias, 1992, Cancer.

The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.

A. Elias, L. Schnipper, K. Antman, 1993, Journal of hematotherapy.

Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.

J. Niloff, K. Anderson, G. Demetri, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support.

C. Begg, T. Shea, J. Eder, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of high-dose methotrexate with citrovorum factor "rescue" in the treatment of osteogenic sarcoma.

N. Jaffe, J. Cassady, R. Filler, 1977, International journal of radiation oncology, biology, physics.

Phase II study of topotecan in metastatic non-small-cell lung cancer.

L. Kalish, T. Lynch, G. Strauss, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin.

P. Richardson, B. Teicher, L. Schnipper, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serial studies of cardiac function in patients receiving adriamycin.

I. Henderson, R. Blum, N. Jaffe, 1978, Cancer treatment reports.

New agents and combination chemotherapy of non-Hodgkin's lymphoma.

J. Gutterman, A. Skarin, E. Frei, 1975, The British journal of cancer. Supplement.

Tumor necrosis factor: still a promising agent.

D. Spriggs, E. Frei, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

GM-CSF potentiated peripheral blood progenitor cell (PBPC) collection with or without bone marrow as hematologic support of high-dose chemotherapy: Two protocols

A. Elias, L. Schnipper, K. Antman, 1991, Breast Cancer Research and Treatment.

Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome.

P. Richardson, A. Elias, L. Schnipper, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support.

A. Elias, R. Gonin, L. Schnipper, 1995, Bone marrow transplantation.

High-Dose Chemotherapy III Breast Cancer

C. Begg, B. Teicher, A. Elias, 1991 .

Intensive combined modality therapy for limited-stage small-cell lung cancer.

J. Eder, A. Elias, C. Wheeler, 1993, Journal of the National Cancer Institute.

A therapeutic trial of maytansine.

L. Parker, R. Mayer, I. Henderson, 1978, Cancer clinical trials.

Four patients with myelodysplastic syndrome with translocation (1;7)(p11;p11) including one patient with independent clones del(1)(q22) and t(1;7)(q21;q11)

M. Shipp, D. Rosenthal, R. Tantravahi, 1988 .

High-dose combined alkylating agent therapy with autologous stem cell support and chest radiotherapy for limited small-cell lung cancer.

A. Elias, L. Schnipper, K. Antman, 1993, Chest.

Successful treatment of metastatic sarcomas with cyclophosphamide, adriamycin, and DTIC (CAD)

J. Greenberger, J. Corson, G. Canellos, 1980, Cancer.

5‐Fluorouracil with cytosine arabinoside in metastatic gastrointestinal cancer

H. Muss, J. Lokich, E. Frei, 1975, Clinical pharmacology and therapeutics.

Clinical trials of hydroxyurea in patients with cancer and leukemia

E. Freireich, P. Carbone, W. Fishbein, 1964, Clinical pharmacology and therapeutics.

Combination chemotherapy followed by radiation therapy in patients with regional stage III unresectable non-small cell lung cancer.

A. Malcolm, D. Amato, A. Skarin, 1985, Cancer treatment reports.

The clinical cancer researcher--still an embattled species.

E. Freireich, E. Frei, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized clinical trials and other approaches in clinical research

E. Frei, 1994, Cancer.

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.

D A Berry, D. Berry, L. Norton, 1998, Journal of the National Cancer Institute.

Improved survival for patients with advanced carcinoma of the head and neck treated with methotrexate‐leucovorin prior to definitive radiotherapy or surgery.

R. Weichselbaum, J. Kirkwood, T. Ervin, 1981, The Laryngoscope.

A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer.

K. Propert, R. Dillman, S. Seagren, 1990, The New England journal of medicine.

Non-small cell lung cancer: novel treatment strategies.

E. Frei, 1997, Chest.

Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support.

D. Schoenfeld, T. Shea, J. Eder, 1988, Archives of dermatology.

Chapter 12 – THE TOXICITY OF HIGH-DOSE BCNU WITH AUTOLOGOUS MARROW SUPPORT1

L. Parker, F. Hochberg, N. Zervas, 1981 .

Prolonged disease-free survival in advanced breast cancer treated with "super-CMF" adriamycin: an alternating regimen employing high-dose methotrexate with citrovorum factor rescue.

R. Gelman, I. Henderson, G. Canellos, 1981, Cancer treatment reports.

A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients.

B. Teicher, T. Shea, J. Eder, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response.

A. Rosowsky, J. Eder, A. Elias, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma.

N. Jaffe, D. Traggis, E. Frei, 1974, The New England journal of medicine.

High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity.

R. Bast, L. Parker, J. Kirkwood, 1980, The American journal of medicine.

Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression.

M. Socinski, S. Cannistra, J. Griffin, 1988, The New England journal of medicine.

Hormonal perturbations in patients with testicular cancer treated with cisplatin

G. LeBlanc, E. Frei, Sze-fong Ng, 1992, Cancer.

Carcinoembryonic antigen: Clinical correlation with chemotherapy for metastatic gastrointestinal cancer

N. Zamcheck, E. Frei, A. Skarin, 1974, Cancer.

ThymidineRequirementsfor the Rescueof PatientsTreated with High-DoseMethotrexat&

S. Howell, G. Boss, K. Herbst, 2006 .

Lack of effectiveness of combined 5‐fluorouracil and methyl‐ccnu therapy in advanced colorectal cancer

R. Mayer, A. Skarin, E. Frei, 1977, Cancer.

High‐dose intravenous and hepatic artery infusions of thymidine

E. Frei, William D. Ensminger, 1978, Clinical pharmacology and therapy.

Phase I trial of combination therapy with PALA and 5-FU.

D. Kufe, R. Johnson, T. Ervin, 1981, Cancer treatment reports.

The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity.

P. Richardson, W. Hryniuk, E Frei, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimens.

J. Eder, A. Elias, M. Seiden, 1992, Bone marrow transplantation.

GM‐CSF mobilized peripheral blood stem cell autografts: The DFCI/BIH experience

A. Elias, L. Schnipper, K. Antman, 1992 .

High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement.

D. Rosenthal, G. Canellos, K. Zuckerman, 1977, Blood.

Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD).

G. Pinkus, D. Rosenthal, G. Canellos, 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An evaluation of the management of patients with cerebral metastases from malignant melanoma

E. Frei, E. Frei, J. Gottlieb, 1972, Cancer.

Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer.

D. Fairclough, A. Elias, L. Schnipper, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined cyclophosphamide, vincristine, and prednisone therapy of malignant lymphoma

E. Gehan, C. Coltman, H. Wilson, 1971, Cancer.

Adverse effects of intrathecal methotrexate in children with acute leukemia in remission.

N. Jaffe, L. Furman, D. Traggis, 1975, Blood.

High-dose methotrexate in osteogenic sarcoma.

N. Jaffe, M. Link, H. Abelson, 1981, National Cancer Institute monograph.

High-dose methotrexate in osteogenic sarcoma: a 5-year experience.

N. Jaffe, D. Traggis, E. Frei, 1978, Cancer treatment reports.

Survival of patients with localized high‐grade soft tissue sarcoma with multimodality therapy: A matched control study

David A. Amato, J. Greenberger, J. Corson, 1983, Cancer.

Four patients with myelodysplastic syndrome with translocation (1;7)(p11;p11) including one patient with independent clones del(7)q22) [corrected] and t(1;7)(q21;q11)

M. Shipp, D. Rosenthal, R. Tantravahi, 1988, Cancer genetics and cytogenetics.

Impact of Chemotherapy on Osteogenic Sarcoma

N. Jaffe, J. Cassady, R. Filler, 1979 .

Prolonged survival of renal allograft in rats by methotrexate-albumin conjugates as immunosuppressive therapy.

J. Stange, D. Wolff, E. Frei, 2008, Transplantation proceedings.

The interval between courses of high-dose chemotherapy with stem cell rescue: therapeutic hypotheses

P. Richardson, C. Bunnell, D. Avigan, 1999, Bone Marrow Transplantation.

New multiple‐agent chemotherapy (B‐DOPA) for advanced Hodgkin's disease

E. Frei, J. Lokich, N. Jaffe, 1976, Cancer.

High‐dose therapy/stem cell support: Comparison of mice and humans

B. Teicher, E. Frei, Jia-En Yuan, 1996, International journal of cancer.

Improved Outcomes From Adding Sequent ia l Pacl i taxe l but Not From Escalat ing Doxorubic in Dose in an Adjuvant Chemotherapy Regimen for Pat ients With Node-Pos i t i ve Pr imary Breast Cancer

D. Berry, R. Schilsky, S. Martino, 2003 .

A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer

G. Demetri, P. Richardson, R. Joyce, 2001, Bone Marrow Transplantation.

Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.

D. Berry, E. Winer, R. Schilsky, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy for head and neck cancer: progress and controversy in the management of patients with M0 disease.

J. Clark, E. Frei, 1989, Seminars in oncology.

Combination chemotherapy with adriamycin‐cyclophosphamide for advanced ovarian carcinoma

C. Griffiths, R. Knapp, R. Gelman, 1980, Cancer.

Pathology of surgery after induction chemotherapy: an analysis of resectability and locoregional control

R. Fabian, C. Norris, S. Tuttle, 1986 .

High-dose methotrexate with citrovorum factor in osteogenic sarcoma--progress report II.

N. Jaffe, J. Cassady, R. Filler, 1977, Cancer treatment reports.

Clinical and scientific considerations in preoperative (neoadjuvant) chemotherapy.

J. Clark, T. Ervin, E. Frei, 1986, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Weekly high‐dose methotrexate‐citrovorum factor in osteogenic sarcoma. Pre‐surgical treatment of primary tumor and of overt pulmonary metastases

N. Jaffe, E. Frei, H. Watts, 1977, Cancer.

Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study

A. Elias, L. Schnipper, K. Antman, 2005, Journal of Cancer Research and Clinical Oncology.

High-dose ifosfamide with mesna uroprotection: a phase I study.

C. Begg, T. Shea, J. Eder, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma.

C. Shapiro, P. Richardson, A. Elias, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies

P. Richardson, D. McDermott, R. Joyce, 2001, Bone Marrow Transplantation.

Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome.

P. Richardson, A. Elias, A. Skarin, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Neoadjuvant chemotherapy in marginally resectable stage III M0 non‐small cell lung cancer: Long‐term follow‐up in 41 patients

M. Jochelson, A. Malcolm, A. Skarin, 1989, Journal of surgical oncology.

High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions.

A. Elias, L. Schnipper, K. Antman, 1994, Seminars in Oncology.

Limb preservation in osteogenic sarcoma: a preliminary report.

K. Fellows, N. Jaffe, G. Vawter, 1977, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Osteogenic sarcoma: alterations in the pattern of pulmonary metastases with adjuvant chemotherapy.

N. Jaffe, H. Abelson, E. Frei, 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose methotrexate in osteogenic sarcoma adjuvant chemotherapy and limb salvage results.

K. Fellows, N. Jaffe, G. Vawter, 1981, Cancer treatment reports.

Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo

B. Teicher, T. Herman, B. Dezube, 1991, International journal of cancer.